2055357-64-5

Nesuparib (JPI-547) is an orally active PARP 1/2 and Tankyrase 1/2 inhibitor involved in the Wnt/β-catenin pathway. Nesuparib can induce cell cycle arrest and apoptosis and has anti-tumor activity. Nesuparib can be used to study cancer, neurological diseases and cardiovascular diseases[1][1][3].

PARP1; PARP2

[1] Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same. Patent WO2016200101A2.
[2] Im S A , et al.A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.[J].Journal of Clinical Oncology, 2021, 39(15_suppl):3113-3113.
[3] Oh K S, et al. JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction[J]. Cancer Research, 2023, 83(7_Supplement): 4496-4496.